Johnson Brand Fraud Marketing Lawsuit Failed

The US Johnson company, which is troubled by bad news, is still out of the mire.

According to reports, in March 14th, the Attorney General of the US Department of justice rejected the settlement agreement reached by the federal prosecutor between Johnson and Philadelphia two months ago, and called for the resuming of negotiations.

Johnson hopes to settle the allegation of illegal marketing of antipsychotic drug Risperdal (Wei Sitong).

2 months ago, Johnson pharmaceuticals Yang Sen pharmaceuticals announced that it had reached a settlement agreement with Texas and would pay $158 million to settle charges against its psychoactive drug Risperdal.

At that time, Johnson said that the settlement agreement would "completely solve all charges against risperidone". Johnson's settlement agreement will cover all claims from 1994 to 2008, and "avoid potential lengthy and expensive appeals".

Today's change means that Johnson will face all accusations against Risperdal again.

The US Department of justice has been investigating Johnson's illegal marketing of anti psychotics Risperdal for many years. Johnson was accused of marketing the drug to treat unapproved indications.

Johnson has said that it is actively coordinating the matter and has already reserved some funds.

Johnson also admitted at the same time that once the settlement fails, Johnson may face criminal or civil proceedings.

Last March, Johnson, a subsidiary of Johnson, Macneil received a $327 million ticket from a judge in South Carolina.

The reason is that the company's antipsychotic drug Risperdal has a deceptive advertising campaign.

John Simmons, the representative of South Carolina, believes that Johnson has written to more than 7000 doctors in South Carolina and praised Risperdal very much, saying it is superior to other companies' medicines.

In addition, Risperdal's warning labels also contain deceptive information.

This is a violation of the United States.

Simmons told the jury that Johnson was in.

Risperdal is the fist product of Johnson. Its global sales hit a high of $4 billion 500 million in 2007, and then began to slide, because the patent protection period ended and began to face cheaper generic competition.

In the middle of 2008, Risperdal sales fell to $3 billion 400 million.

In addition to marketing irregularities, Risperdal is also suspected of selling outside indications.

According to reports, Johnson is in

It is worth mentioning that the drug is also sold in China. The Chinese name, Risperdal, was introduced into China in the late 90s of last century by Yang Sen company of Xi'an. The official website of Xi'an, Xi'an showed that Risperdal had two formulations of tablets and oral liquid, and all indications were for schizophrenia, bipolar disorder and related symptoms.

Among them, oral liquid is imported, and tablets are produced by Yang Sen, Xi'an.

The public relations department of Xi'an Yang Sen company said that risperdin had already approved the indication of bidirectional affective disorder in China.

"At present, China does not have much information on this issue, and if necessary, it will make a statement in the future."

The lawsuit against suspected exaggeration in risperidone's marketing is no longer the first time in the United States.

Earlier, the state of Pennsylvania accused Johnson of "hiding the risk of diabetes after the use of drugs and inducing the departments concerned to pay higher for the drug".